<?xml version="1.0" encoding="UTF-8"?>
<p>Besides peptides, mAb, and protein chimeras, small molecules are still the preferred modality for a drug. This is due to improved pharmacokinetics, stability, and dosage logistics compared to proteins or peptides.
 <sup>
  <xref ref-type="bibr" rid="ref54">54</xref>,
  <xref ref-type="bibr" rid="ref55">55</xref>
 </sup> In addition, small molecules have advantages compared to peptides/proteins regarding dissemination logistics in remote areas and the high expenses of peptide/protein production.
 <sup>
  <xref ref-type="bibr" rid="ref54">54</xref>,
  <xref ref-type="bibr" rid="ref55">55</xref>
 </sup>
</p>
